Topical immunotherapy: what's new.
Further understanding of the pathogenesis of dermatologic conditions at a molecular level has led to targeted therapies. The topical immune response modifiers have contributed significantly to the treatment of cutaneous diseases. New topical remedies, particularly the Toll-like receptor agonists and calcineurin inhibitors, have added to the clinical armamentarium and have further advanced clinicians' ability to treat a wide variety of benign, premalignant, and malignant conditions. Furthermore, these agents have contributed to the understanding of the disease process. The next decade will witness even greater advances in targeted immunotherapies for dermatologic disease.
Sauder
Daniel N
DN
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205-0900, USA. dsauder@jhmi.edu
Mofid
Mona Z
MZ
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000279:Administration, Cutaneous; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D008562:Membrane Glycoproteins / Q000819:agonists; D011956:Receptors, Cell Surface / Q000819:agonists; D012871:Skin Diseases / Q000628:therapy*; D051193:Toll-Like Receptors
D000276:Adjuvants, Immunologic; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D008562:Membrane Glycoproteins; D011956:Receptors, Cell Surface; D051193:Toll-Like Receptors